This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dimopoulos, M. A. Articles by Treon, S. P. Search for Related Content PubMed PubMed Citation Articles by Dimopoulos, M. A. Articles by Treon, S. P. Social Bookmarking                            What's this?

Diagnosis and Management of Waldenstrom's Macroglobulinemia

From the Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; Division of Hematology, Mayo Clinic, Rochester, NY; Department of Hematology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Address reprint requests to Meletios A. Dimopoulos, MD, 227 Kifissias Ave, Kifissia, Athens, 14561, Greece; e-mail: mdimop{at}med.uoa.gr

PURPOSE: To review the diagnostic criteria, prognostic factors, response criteria, and treatment options of patients with Waldenstrom's macroglobulinemia (WM).

METHODS: A review of published reports was facilitated by the use of a MEDLINE computer search and by manual search of the Index Medicus.

RESULTS: WM should be regarded as a distinct clinicopathologic entity and confined to those patients with lymphoplasmacytoid lymphoma who have demonstrable serum immunoglobulin M monoclonal protein. Treatment decisions should rely on specific clinical and laboratory criteria. Initiation of therapy should not be based on serum monoclonal protein levels per se. The three main choices for systemic primary treatment of symptomatic patients with WM include alkylating agents (chlorambucil), nucleoside analogs (fludarabine and cladribine), and the monoclonal antibody rituximab. There are no data from prospective randomized studies to recommend the use of one first-line agent over another, although consideration of a patient's candidacy for autologous stem-cell transplantation (ASCT) should be taken into account to avoid stem cell–damaging agents. There are preliminary data to suggest that combinations of nucleoside analogs and alkylating agents with or without rituximab may improve response rates at the expense of higher toxicity.

CONCLUSION: WM is a distinct low-grade lymphoproliferative disorder. When therapy is indicated, alkylating agents, nucleoside analogs, and rituximab are reasonable choices. Several factors, including the presence of cytopenias, need for rapid disease control, candidacy for ASCT, age, and comorbidities, should be taken into consideration when choosing the most appropriate primary treatment.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Prasad, A. Maitra, N. Sethiya, V K Bharadwaj, V. Chowdhury, J. Valecha, and R. Biswas Acute renal failure followed by low back ache BMJ Case Reports, November 3, 2009; 2009(nov03_1): bcr0320091726 - bcr0320091726. [Full Text]

				P. Morel, A. Duhamel, P. Gobbi, M. A. Dimopoulos, M. V. Dhodapkar, J. McCoy, J. Crowley, E. M. Ocio, R. Garcia-Sanz, S. P. Treon, et al. International prognostic scoring system for Waldenstrom macroglobulinemia Blood, April 30, 2009; 113(18): 4163 - 4170. [Abstract] [Full Text] [PDF]

				M. V. Dhodapkar, A. Hoering, M. A. Gertz, S. Rivkin, J. Szymonifka, J. Crowley, and B. Barlogie Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003 Blood, January 22, 2009; 113(4): 793 - 796. [Abstract] [Full Text] [PDF]

				M. A. Dimopoulos, E. Kastritis, S. Delimpassi, A. Zomas, M. C. Kyrtsonis, and K. Zervas The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens Haematologica, September 1, 2008; 93(9): 1420 - 1422. [Full Text] [PDF]

				Q. Bashir, C.-K. Lee, R. W. Stuart, M. L. Smith, J. Ryder, and R. Gonzalez Phenotypic Evolution of Waldenstrom's Macroglobulinemia to Extramedullary Plasmacytoma J. Clin. Oncol., May 10, 2008; 26(14): 2408 - 2410. [Full Text] [PDF]

				M. N. Menke, G. T. Feke, J. W. McMeel, and S. P. Treon Effect of Plasmapheresis on Hyperviscosity-Related Retinopathy and Retinal Hemodynamics in Patients with Waldenstrom's Macroglobulinemia Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1157 - 1160. [Abstract] [Full Text] [PDF]

				S. P. Treon, Z. R. Hunter, J. Matous, R. M. Joyce, B. Mannion, R. Advani, D. Cook, J. Songer, J. Hill, B. R. Kaden, et al. Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248 Clin. Cancer Res., June 1, 2007; 13(11): 3320 - 3325. [Abstract] [Full Text] [PDF]

				E. Hatjiharissi, H. Ngo, A. A. Leontovich, X. Leleu, M. Timm, M. Melhem, D. George, G. Lu, J. Ghobrial, Y. Alsayed, et al. Proteomic Analysis of Waldenstrom Macroglobulinemia Cancer Res., April 15, 2007; 67(8): 3777 - 3784. [Abstract] [Full Text] [PDF]

				M. N. Menke, G. T. Feke, J. W. McMeel, A. Branagan, Z. Hunter, and S. P. Treon Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia. Arch Ophthalmol, November 1, 2006; 124(11): 1601 - 1606. [Abstract] [Full Text] [PDF]

				A. Wiestner Gene expression relates WM to CLL Blood, October 15, 2006; 108(8): 2499 - 2500. [Full Text] [PDF]

				S. V. Rajkumar, A. Dispenzieri, and R. A. Kyle Monoclonal Gammopathy of Undetermined Significance, Waldenstrom Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment Mayo Clin. Proc., May 1, 2006; 81(5): 693 - 703. [Abstract] [Full Text] [PDF]